---
title: "Catalyst Pharmaceuticals Announced Transfer or Voluntary Withdrawal of Listing"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292887983.md"
description: "Catalyst Pharmaceuticals announced its intention to delist from Nasdaq following a merger. On July 15, 2026, the company notified Nasdaq to file Form 25 for deregistration. Trading is suspended on July 16, 2026, with plans to file Form 15 to terminate SEC reporting obligations once Form 25 becomes effective."
datetime: "2026-07-16T10:03:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292887983.md)
  - [en](https://longbridge.com/en/news/292887983.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292887983.md)
---

# Catalyst Pharmaceuticals Announced Transfer or Voluntary Withdrawal of Listing

On July 15, 2026, the company notified Nasdaq that, following the consummation of its merger, it intends to remove its common stock from Nasdaq and requested that Nasdaq file a Form 25 to delist and deregister the shares. Trading will be suspended on July 16, 2026, and the company plans to file a Form 15 to terminate registration and suspend reporting obligations after the Form 25 becomes effective.

Original SEC Filing: CATALYST PHARMACEUTICALS, INC. \[ CPRX \] - 8-K - Jul. 15, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [CPRX.US](https://longbridge.com/en/quote/CPRX.US.md)

## Related News & Research

- [Netcapital says SEC stay halts Nasdaq $5 million market-value delisting rule pending review](https://longbridge.com/en/news/294513835.md)
- [Governance Red Flags at U.S. Gold Corp: Control Weaknesses, Late SEC Filings and Nasdaq Compliance Risk](https://longbridge.com/en/news/294476139.md)
- [Scorpio Gold pursues Nasdaq listing for American depositary shares](https://longbridge.com/en/news/293905134.md)
- [Electro-Sensors shares set to exit Nasdaq after merger; company plans SEC deregistration](https://longbridge.com/en/news/294552623.md)
- [AWK: Q2 2026 EPS increased to $1.61, with guidance and long-term growth targets reaffirmed](https://longbridge.com/en/news/294261314.md)